Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19 - A Multicenter Randomized Double Blind Placebo Controlled Clinical Trial in Bangladesh

NCT05056558 is registered in ClinicalTrials.gov with Incepta Pharmaceuticals Ltd as lead sponsor.

NCT NCT05056558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05056558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19 - A Multicenter Randomized Double Blind Placebo Controlled Clinical Trial in Bangladesh
Lead sponsor
Incepta Pharmaceuticals Ltd
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2021
Completion date
September 30, 2022
Enrollment
480 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19